Barclays (LON:BARC) analyst Steven Valiquette maintained a Buy rating on DaVita (NYSE:DVA) on Friday, setting a price target of $135, which is approximately 13.68% above the present share price of $118.75.
Valiquette expects DaVita to post earnings per share (EPS) of $1.31 for the first quarter of 2021.
The current consensus among 6 TipRanks analysts is for a Moderate Buy rating of shares in DaVita, with an average price target of $128.2.
The analysts price targets range from a high of $150 to a low of $99.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $2.92 billion and a net profit of $432.17 million. The company's market cap is $13.29 billion.
According to TipRanks.com, Barclays analyst Steven Valiquette is currently ranked with 3 stars on a 0-5 stars ranking scale, with an average return of 3.1% and a 56.82% success rate.
DaVita, Inc. engages in the provision of medical care services. It operates through the following two segments: US Dialysis and Related Lab Services; and Other-Ancillary Services and Strategic Initiatives. The US Dialysis and Related Lab Services segment offers kidney dialysis services in the United States for patients suffering from chronic kidney failure. The Other-Ancillary Services and Strategic Initiatives segment consist primarily of pharmacy services, disease management services, vascular access services, clinical research programs, physician services, direct primary care, end stage renal disease seamless care organizations, and comprehensive care. The company was founded in 1994 and is headquartered in Denver, CO.